Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|71|1-2|40-48

ISSN： 0030-2414

Source： Oncology, Vol.71, Iss.1-2, 2007-04, pp. : 40-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer

By Shiroiwa Takeru   Motoo Yoshiharu  

Molecular Diagnosis & Therapy, Vol. 14, Iss. 6, 2010-12 ,pp. : 375-384

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Colorectal Cancer Screening

By Lansdorp-Vogelaar Iris   Knudsen Amy B.   Brenner Hermann  

Epidemiologic Reviews, Vol. 33, Iss. 1, 2011-05 ,pp. : 88-100

Oxford University Press

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite